Cubist profits halved on Adolor buyout; CHMP backs Novartis drug for Cushing's;

@FiercePharma: Why do more than half of doctors oppose mandatory HPV vax? Check the latest from . Survey | Follow @FiercePharma

> Cubist Pharmaceuticals ($CBST) said fourth-quarter profits fell by more than half because of costs stemming from its acquisition of Adolor. Story

> The European Committee for Medicinal Products for Human Use recommended that Novartis' ($NVS) drug Signifor be approved for use against the rare endocrine disorder Cushing's disease. Report

> Otsuka Pharmaceutical won a new bipolar-mania indication in Japan for its antipsychotic drug Abilify. Report

> A federal judge in Boston ordered 14 drug companies to negotiate settlements with 53 patients who allege their breast cancer was triggered by a synthetic hormone their mothers used. Story

> Bristol-Myers Squibb ($BMY) has donated $6.9 million to the HealthWell Foundation to help cancer patients pay for their treatment. Article

> AstraZeneca ($AZN) bought back 467,864 shares for 3063 pence a share as part of its ongoing share-buyback plan. Report

> India's Glenmark Pharmaceuticals has won the FDA's nod for its versions of two Ortho-McNeil Janssen oral contraceptives. News

Biotech News

@FierceBiotech: Quintiles to hire 500 for new BPO hub in China, where the giant CRO has a growing presence. Story | Follow @FierceBiotech

@JohnCFierce: Trounson on the effect of Geron ESC exit: "a very strong negative influence internationally." Item | Follow @JohnCFierce

@RyanMFierce: Sanofi's Viehbacher to FDA: We need clear risk-benefit guidance to invest in primary care drugs. Article | Follow @RyanMFierce

@MarkHFierce: Scientists are up in arms in CA about plunging state funding support for research. More | Follow @MarkHFierce

@FierceMedDev: Interesting. Faulty French Breast Implants May Upend U.S. Device Debate--Bloomberg. News | Follow @FierceMedDev

> Amgen, Biogen jump into copycat game amid string of biosimilars deals. Story

> Alnylam cutting third of jobs to devote cash to lead RNAi programs. News

And Finally... PhRMA chair and Sanofi CEO Chris Viehbacher (photo) called on the FDA for clearer guidelines for approval of new primary care drugs. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.